Anteris Technologies (ASX:AVR) advances 3D single-piece heart valve

SoniaInterview

  • Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise
  • On Thursday, the company entered a trading halt, pausing shares until Monday, August 2
  • It is unknown how much the company is planning to raise or where the funds will be spent
  • On the market, Anteris last traded at $8.59 per share

Anteris Technologies (AVR) has paused trading as it plans for an upcoming capital raise.

On Thursday, the company entered a trading halt, pausing shares until Monday, August 2.

Currently, it is unknown how much the company is planning to raise or where the funds will be spent.

Anteris is a structural heart company, providing solutions for heart valves.

Earlier this week, the company received a patent from the Australian Patent Office for its sterilised packaging system for catheters.

The patent is for 20 years from July 16, 2018.

In June, Anteris' finished the proof-of-concept animal study on conduits treated with its Adapt tissue technology in the carotid artery.

Conduits treated with the Adapt process showed no evidence of calcification as indicated by histopathology. The company said the results further validate its anti-calcification properties in highly problematic areas of surgery.

Watch the interview here